Literature DB >> 26156326

Next-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?

Arnaud Uguen1, Matthieu Talagas2, Pascale Marcorelles2, Paul Guéguen3, Sebastian Costa4, Sophie Andrieu-Key4, Marc De Braekeleer5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26156326      PMCID： PMC4524757          DOI： 10.1634/theoncologist.2015-0123

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Authors:  Marina Pekar-Zlotin; Fred R Hirsch; Lior Soussan-Gutman; Maya Ilouze; Addie Dvir; Theresa Boyle; Murry Wynes; Vincent A Miller; Doron Lipson; Gary A Palmer; Siraj M Ali; Shlomi Dekel; Ronen Brenner; Paul A Bunn; Nir Peled
Journal:  Oncologist       Date:  2015-02-26

3.  Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.

Authors:  M I Ilie; C Bence; V Hofman; E Long-Mira; C Butori; L Bouhlel; S Lalvée; J Mouroux; M Poudenx; J Otto; C H Marquette; P Hofman
Journal:  Ann Oncol       Date:  2014-10-24       Impact factor: 32.976

4.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

5.  Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

Authors:  Florian Cabillic; Audrey Gros; Frédéric Dugay; Hugues Begueret; Laura Mesturoux; Dan Cristian Chiforeanu; Leila Dufrenot; Vincent Jauffret; Dominique Dachary; Romain Corre; Alexandra Lespagnol; Gwendoline Soler; Julien Dagher; Véronique Catros; Michèle Le Calve; Jean-Philippe Merlio; Marc-Antoine Belaud-Rotureau
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609
  5 in total
  1 in total

1.  In Reply.

Authors:  Nir Peled
Journal:  Oncologist       Date:  2015-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.